{"id":"levofloxacin-azithromycin-amoxicillin-clavulanate","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Levofloxacin inhibits DNA gyrase and topoisomerase IV, preventing DNA replication. Azithromycin binds to the 50S ribosomal subunit, inhibiting protein synthesis. Amoxicillin/clavulanate works by disrupting bacterial cell wall synthesis, with clavulanate protecting amoxicillin from degradation by beta-lactamases.","oneSentence":"Levofloxacin, azithromycin, and amoxicillin/clavulanate inhibit bacterial growth through different mechanisms, targeting DNA gyrase, protein synthesis, and cell wall synthesis, respectively.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:26.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Acute bacterial sinusitis"},{"name":"Uncomplicated skin and skin structure infections"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT05293977","phase":"NA","title":"Short-Term Use of Antibiotics and Adherence Level","status":"COMPLETED","sponsor":"Jordan University of Science and Technology","startDate":"2020-08-03","conditions":"Acute Infection","enrollment":589},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT00042718","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-11","conditions":"Bronchitis, Chronic Bronchitis","enrollment":659}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"levofloxacin, azithromycin, amoxicillin/clavulanate","genericName":"levofloxacin, azithromycin, amoxicillin/clavulanate","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levofloxacin, azithromycin, and amoxicillin/clavulanate inhibit bacterial growth through different mechanisms, targeting DNA gyrase, protein synthesis, and cell wall synthesis, respectively. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Uncomplicated skin and skin structure infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}